{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:19:45Z","timestamp":1783657185370,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.clineuro.2007.01.011","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T07:16:36Z","timestamp":1172042196000},"page":"350-353","source":"Crossref","is-referenced-by-count":14,"title":["Assessment of valvulopathy in Parkinson's disease patients on pergolide and\/or cabergoline"],"prefix":"10.1016","volume":"109","author":[{"given":"G\u00fclay","family":"Kenangil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"\u00d6zekmek\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Koldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylan","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethem","family":"Ergin\u00f6z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2007.01.011_bib1","series-title":"Principles of Treatment in Parkinson's Disease","first-page":"25","article-title":"Drug therapy: dopamine agonists","author":"Poewe","year":"2005"},{"key":"10.1016\/j.clineuro.2007.01.011_bib2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.clineuro.2005.02.002","article-title":"Treatment of motor dysfunction in Parkinson's disease: an overview","volume":"107","author":"Thobois","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.clineuro.2007.01.011_bib3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide","volume":"77","author":"Pritchett","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clineuro.2007.01.011_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","article-title":"The US food and drug administration's registry of patients with pergolide-associated valvular heart disease","volume":"78","author":"Flowers","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clineuro.2007.01.011_bib5","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","article-title":"Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide","volume":"61","author":"Van Camp","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2007.01.011_bib6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.clineuro.2007.01.011_bib7","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2007.01.011_bib8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","article-title":"Pergolide use in Parkinson disease is associated with cardiac valve regurgitation","volume":"63","author":"Baseman","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2007.01.011_bib9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","article-title":"Valvular heart disease in Parkinson's disease vs. controls: an echocardiographic study","volume":"21","author":"Peralta","year":"2006","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"10.1016\/j.clineuro.2007.01.011_bib10","first-page":"A48","article-title":"Heart valve disease in PD patients treated with dopamine agonists","volume":"66","author":"Antonini","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 10","key":"10.1016\/j.clineuro.2007.01.011_bib11","first-page":"S79","article-title":"Cardiac valve abnormalities in patients with Parkinson's disease","volume":"20","author":"Reuter","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2007.01.011_bib12","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJM200511033531822","article-title":"Cabergoline-related severe restrictive mitral regurgitation","volume":"353","author":"Pinero","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clineuro.2007.01.011_bib13","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00702-005-0289-1","article-title":"Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline","volume":"112","author":"Dhawan","year":"2005","journal-title":"J Neural Transm"},{"issue":"Suppl 10","key":"10.1016\/j.clineuro.2007.01.011_bib14","first-page":"S84","article-title":"Valvular heart disease associated with low cumulative dose of pergolide in the patient with Parkinson's disease","volume":"20","author":"Chung","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2007.01.011_bib15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","article-title":"What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study","volume":"42","author":"Hughes","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.clineuro.2007.01.011_bib16","series-title":"Recent Developments in Parkinson's Disease","first-page":"153","article-title":"Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale","author":"Fahn","year":"1987"},{"key":"10.1016\/j.clineuro.2007.01.011_bib17","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/mds.20210","article-title":"Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table","volume":"19","author":"Grosset","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2007.01.011_bib18","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/mds.21225","article-title":"Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study","volume":"22","author":"Junghanns","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2007.01.011_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clineuro.2007.01.011_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clineuro.2007.01.011_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/mds.20931","article-title":"Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists","volume":"21","author":"Kim","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clineuro.2007.01.011_bib22","first-page":"221","article-title":"Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease","volume":"46","author":"Murakim","year":"2005","journal-title":"J Cardiol"},{"key":"10.1016\/j.clineuro.2007.01.011_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0404.2005.00514.x","article-title":"Efficacy and safety of high dose cabergoline in Parkinson's disease","volume":"113","author":"Odin","year":"2006","journal-title":"Acta Neurol Scand"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384670700025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384670700025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T00:27:21Z","timestamp":1546993641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030384670700025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S030384670700025X"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2007.01.011","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}